Efficacy and safety of efpeglenatide in key patient subgroups from the BALANCE randomized trial, stratified by pre-diabetes status, BMI, and age at baseline

Article Authors: Richard E Pratley, Stephan Jacob, Seungjae Baek, Michael E Trautmann, Marcus Hompesch, OakPil Han, John Stewart, Christopher H Sorli, Alka Shaunik, Kun-Ho Yoon

no alt text set

Abstract

Efpeglenatide is a long-acting glucagon-like peptide-1 receptor agonist being developed to improve glycemic control in type 2 diabetes (T2D). In the BALANCE 205 study (NCT02075281), efpeglenatide significantly reduced body weight versus placebo in patients with obesity, or overweight with comorbidities, and without T2D. These subanalyses explore the efficacy and safety of efpeglenatide in subgroups of patients with pre-diabetes and stratified by body mass index (BMI) or age from the BALANCE study.

no